What is the role of CRP as a marker of risk and as a possible target of therapy for CVD risk reduction?

Expert opinion by Peter Libby, MD, Chief, Cardiovascular Medicine, Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, USA